| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/23/2006 | US20060040981 Use of phosphodiesterase-4 inhibitors as enhancers of cognition |
| 02/23/2006 | US20060040980 Ionophores as cancer chemotherapeutic agents |
| 02/23/2006 | US20060040979 3-Aryl-2-hydroxypropionic acid derivative I |
| 02/23/2006 | US20060040978 5-HT7 receptor antagonists |
| 02/23/2006 | US20060040977 N-[3-(3,4-Dihydro-1H-isoquinolin-2-yl)-propyl]-2-methyl-5-nitro-benzenesulfonamidehydrochloride; selective ligands of the 5-HT7 receptor; treating Central nervous system, pain, sleep disorder, shift worker syndrome, jet lag, depression, seasonal affective disorder, migraine, anxiety, psychosis |
| 02/23/2006 | US20060040976 Thiobenzimidazole derivatives |
| 02/23/2006 | US20060040975 Fused ring NK1 antagonists |
| 02/23/2006 | US20060040974 Decahydroisoquinolinyl- hydroxyethylamine derivatives; human immunodeficiency virus (HIV) protease |
| 02/23/2006 | US20060040973 Novel guanidine mimics as factor Xa inhibitors |
| 02/23/2006 | US20060040972 Pyrazolonaphthyridine derivative |
| 02/23/2006 | US20060040971 Dissolving amorphous rapamycin in t-butyl methyl ether and recrystallizing rapamycin to form rapamycin form II; differential scanning calorimetry thermogram lacking an endotherm peak of about 194 degrees; lower melting point than rapamycin, more readily compressible |
| 02/23/2006 | US20060040970 Administering 4,5 alpha -epoxy-6 beta -(3,4-dihydro-2H-benzo[1,4]thiazino)-3-methoxy-17-methyl-morphinan; for urinary frequency, therapeutic or prophylactic effect and of which side effects are improved |
| 02/23/2006 | US20060040969 Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of P450 isoenzyme 3A4 |
| 02/23/2006 | US20060040968 2-(Amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| 02/23/2006 | US20060040967 6-Fluoroalkyl-4-(5-sulfonyl-2-pyridyl)-substituted, e.g., 4-(5-Methanesulfonyl-pyridin-2-yl)-6-trifluoromethyl-pyrimidin-2-yl]-methyl-(6-methyl-pyridin-2-ylmethyl)-amine; treating pain, fever and inflammation without the potential side effects of other COX inhibitors |
| 02/23/2006 | US20060040966 e.g. 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide; Vascular Endothelial Growth Factor antagonist; angiogenesis inhibitor; anticarcinogenic, antiinflammatory inhibitor; retinopathies, rheumatoid arthritis, asthma, atherosclerosis, endometriosis, neoplastic diseases |
| 02/23/2006 | US20060040965 (5,6-Diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(2-morpholin-4-ylethyl)-amine; activated p21cdc42Hs-associated kinase (ACK1) and leukocyte specific protein tyrosine kinase (LCK) inhibitor; antiproliferative and antiinflammatory agent; cancer, osteoporosis |
| 02/23/2006 | US20060040964 Eating disorders; psychological disorders; antidiabetic agents; cardiovascular disorders |
| 02/23/2006 | US20060040963 Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 02/23/2006 | US20060040962 Pharmaceutical formulations |
| 02/23/2006 | US20060040961 N-isopropyl-5-phenyl-6-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)furo[2,3-d]pyrimidin-4-amine; inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's |
| 02/23/2006 | US20060040960 (3-amino-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-2-yl)-(2,5-dimethoxyphenyl)methanone; antiproliferative agent; solid tumors: breast, respiratory tract, brain, reproductive organs, digestive tract, liver, skin, head and neck, thyroid, and their metastases; lymphomas, sarcomas, and leukemias |
| 02/23/2006 | US20060040959 Adenosine A3 receptor modulators |
| 02/23/2006 | US20060040958 Antiproliferative agents; anticancer agents; antiinflammatroy agents; Alzheimer's disease; viricides; fungicides |
| 02/23/2006 | US20060040957 Bicyclic pyrimidine matrix metalloproteinase inhibitors |
| 02/23/2006 | US20060040956 Substituted alkylamine derivatives and methods of use |
| 02/23/2006 | US20060040955 4-pyrimidineamine compounds and their uses as anti-proliferative agents |
| 02/23/2006 | US20060040954 Soluble amide & ester pyrazinoylguanidine sodium channel blockers |
| 02/23/2006 | US20060040953 dry powder therapeutic agent containing an aniton selected from 3,6-di(succinate-4-aminobutyl)-2,5-diketopiperazine, 3,6-di(fumarate-4-aminobutyl)-2,5-diketopiperazine; cation is selected from Na, K, Ca, Li, triethylamine, butylamine, diethanolamine and triethanolamine; and a drug; dry powder |
| 02/23/2006 | US20060040952 Il-8 receptor antagonists |
| 02/23/2006 | US20060040951 Use of 5-ht2 receptor antagonists for the treatment of sleep disorders |
| 02/23/2006 | US20060040950 Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| 02/23/2006 | US20060040949 Treating antibiotic resistant bacterial infections; compounds based on quinoline rings; (3S)-2-(3-{[(Benzo[1,2,5]thiadiazol-5-ylmethyl)-amino]-methyl}-piperidin-1-yl)-(1RS)-(6-methoxy-quinolin-4-yl)-ethanol for example |
| 02/23/2006 | US20060040948 Cognitive or neurodegenerative disease; Alzheimer's disease; HMG-CoA reductase inhibitors, gamma-secretase inhibitors, non-steroidal anti-inflammatory agents, N-methyl-D-aspartate receptor antagonists, cholinesterase inhibitors and anti-amyloid antibodies |
| 02/23/2006 | US20060040947 inflammation; N-(4-Phenylpyridin-2-yl)isoquinolin-5-amine; analgesis; antinociceptive agents |
| 02/23/2006 | US20060040946 tetrahydrobiopterin, BH4; hyperphenylalaninemia; phenylketonuria; replace or supplement and alleviate the dietary restrictions under which a PKU patient is placed; enhancement of nitric oxide synthase activity; protein-restricted diet and BH4 is effective to lower plasma phenylalanine |
| 02/23/2006 | US20060040945 Annellated pyrrole compounds as proton pump inhibitors for treating ulcer |
| 02/23/2006 | US20060040944 5-Aza-7-deazapurine derivatives for treating Flaviviridae |
| 02/23/2006 | US20060040943 3-Furanyl analogs of toxoflavine as kinase inhibitors |
| 02/23/2006 | US20060040942 Antiinflammatory agents; autoimmune disease |
| 02/23/2006 | US20060040941 7-Aminoimidazotriazones |
| 02/23/2006 | US20060040940 Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands |
| 02/23/2006 | US20060040939 Benzamide inhibitors of the P2X, receptor |
| 02/23/2006 | US20060040938 Substituted fullerene compositions and their use as antioxidants |
| 02/23/2006 | US20060040937 N-aroyl cyclic amines as orexin receptor antagonists |
| 02/23/2006 | US20060040936 Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors |
| 02/23/2006 | US20060040935 Method of treating impotence due to spinal cord injury |
| 02/23/2006 | US20060040934 Use of STAT-6 inhibitors as therapeutic agents |
| 02/23/2006 | US20060040933 Antiinflammatory agents |
| 02/23/2006 | US20060040932 Stable crystalline form of bifeprunox mesylate (7-[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate) |
| 02/23/2006 | US20060040931 Benzomorpholine derivatives |
| 02/23/2006 | US20060040930 Novel substituted [1,4] benzodioxino[2,3-e] isoindole derivatives, method for preparing and pharmaceutical compositions containing same |
| 02/23/2006 | US20060040929 (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione and method of preparation thereof |
| 02/23/2006 | US20060040928 amyloid precursor protein and gamma -secretase inhibitor; 3,4,6,7,8,9-Hexahydro-2-methyl-3-oxo-2H-naphtho[2,3-e]-1,2-thiazine-4-carboxanilide 1,1-dioxide; neurodegenerative disease: Alzheimer's disease, amyloid plaque, Parkinson's disease, Down's syndrome, hemorrhage, arteriosclerosis |
| 02/23/2006 | US20060040927 Heterocyclic antiviral compounds |
| 02/23/2006 | US20060040926 Fluorescent fused-ring triazoles that inhibit cell proliferation and uses thereof |
| 02/23/2006 | US20060040925 Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity |
| 02/23/2006 | US20060040924 Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of renal colic |
| 02/23/2006 | US20060040923 1,1-Diethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea; respiratory syncytial virus; cost efficient replacement for Synagis (palivizumab) used for RSV; respiratory system disorders; asthna; viral diseases; myxoviruses; mumps; flaviviruses; dengue, West Nile, parainfluenza viruses |
| 02/23/2006 | US20060040922 Aripiprazole, olanzapine and haloperidol pamoate salts |
| 02/23/2006 | US20060040921 Process and intermediates for the preparation of olanzapine |
| 02/23/2006 | US20060040920 Crystal forms of olanzapine and processes for their preparation |
| 02/23/2006 | US20060040919 N-substituted-(dihydroisoquinoline or tetrahydro 2- or 3- benzazepine)-2-carbothioamides; blocking agents; asthma, chronic obstructive pulmonary disease, bronchiectasis, cystic fibrosis, bronchiolitis or bronchopulmonary dysplasia; coadministering with a beta 2-agonist, anticholinergic agent or corticoid |
| 02/23/2006 | US20060040918 Benzo d!azepine derivatives for the treatment of neurological disorders |
| 02/23/2006 | US20060040917 Benzoxazepine derivatives as selective estrogen receptor modulators |
| 02/23/2006 | US20060040916 Carbapenem compound crystals and injection preparations |
| 02/23/2006 | US20060040915 Process for the preparation of cefdinir |
| 02/23/2006 | US20060040914 Meso-substituted porphyrins |
| 02/23/2006 | US20060040913 2-Aza-21-carba-5,10,15,20-tetra(3-methoxyphenyl)prophyrin (NC-m-TMPP; for photodynamic therapy, of cancerous and other diseased tissues, Barrett's Oesophagus, ARMD, keratinosis, diabetic neuropathy, peripheral vascular disease, coronary artery disease, disorders arising from bacterial or viral infection |
| 02/23/2006 | US20060040912 Compounds for pdt |
| 02/23/2006 | US20060040911 Method for preventing and/or treating the cardiovascular and hepatic diseases induced by hyperlipidemia which comprises administered an effective amount of bioflavonoids extract derived from fructus crataegus (lipid metabolism and fructus crataegus) |
| 02/23/2006 | US20060040910 Macrocycles useful in the treatment of Alzheimer's disease |
| 02/23/2006 | US20060040909 Selenophene compounds |
| 02/23/2006 | US20060040908 Novel chalcogenoxanthylium dyes for purging blood pathogens and for photodynamic therapy |
| 02/23/2006 | US20060040907 Triptolide analogs for the treatment of autoimmune and inflammatory disorders |
| 02/23/2006 | US20060040906 Piperazine urea derivatives as melanocortin-4 receptor agonists |
| 02/23/2006 | US20060040905 Formulation of nefopam and its use in the treatment of pain |
| 02/23/2006 | US20060040904 sodium 17 alpha/17-beta-estradiol sulfate, sodium 17 alpha/17 beta-dihydroequilin sulfate, sodium estrone sulfate, sodium equilin sulfate, sodium 17 alpha/ 17-beta -dihydroequilenin sulfate, sodium equilenine sulfate, sodum estrone sulfate, butyleated hydroxyanisole stabilizer; menopausal conditions |
| 02/23/2006 | US20060040903 Methods of use related to xerostomia |
| 02/23/2006 | US20060040901 Derivatives of 1,3-cyclic propandiol phosphate and their action as cell stimulants |
| 02/23/2006 | US20060040900 R(-)-10-methoxy-11-O-acetyl-N-n-propyl-noraporphine; Parkinson's disease, sexual dysfunction, and depressive disorders |
| 02/23/2006 | US20060040899 Medicaments containing bisphosphonic acids and derivatives thereof for preventing and treating diseases and allergies |
| 02/23/2006 | US20060040898 Novel boronate esters |
| 02/23/2006 | US20060040897 Compositions for treating and/or preventing diseases characterized by the presence of metal ions |
| 02/23/2006 | US20060040896 Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity |
| 02/23/2006 | US20060040895 Aesthetic use of hyaluronan |
| 02/23/2006 | US20060040894 Compositions and methods using hyaluronic acid |
| 02/23/2006 | US20060040893 Immunomodulatory methods using oligosaccharides |
| 02/23/2006 | US20060040892 Process for synthesizing oil and surfactant-free hyaluronic acid nanoparticles and microparticles |
| 02/23/2006 | US20060040891 Lipid a and other carbohydrate ligand analogs |
| 02/23/2006 | US20060040890 4-Amino-1-((2R,3S,4S,5R)-5-azido-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one; hepatitis C virus. |
| 02/23/2006 | US20060040889 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
| 02/23/2006 | US20060040888 2-propynyl adenosine analogs with modifed 5'-ribose groups having A2A agonist activity |
| 02/23/2006 | US20060040887 Method for stimulating the immune, inflammatory or neuroprotective response |
| 02/23/2006 | US20060040886 heat shock protein 27 inhibitors; RNA interference; nuclease resistance |
| 02/23/2006 | US20060040885 Bioprosthetic heart valves |
| 02/23/2006 | US20060040876 Modulation of peroxisome proliferator-activated receptors |
| 02/23/2006 | US20060040875 Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B) |
| 02/23/2006 | US20060040874 Process for the preparation of topiramate |
| 02/23/2006 | US20060040873 Composition for use in prophylaxis and or treatment |